Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 한평림 | - |
dc.date.accessioned | 2016-08-28T12:08:34Z | - |
dc.date.available | 2016-08-28T12:08:34Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0378-8741 | - |
dc.identifier.other | OAK-6801 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/220976 | - |
dc.description.abstract | Ethnopharmacological relevance: The oriental medicine Jangwonhwan, which is a boiled extract of 12 medicinal herbs/mushroom, has been prescribed for patients with cognitive dysfunction. Recently, a modified recipe of Jangwonhwan (LMK02-Jangwonhwan) consisting of seven medicinal plants/mushroom, was shown to have a therapeutic potential to ameliorate AD-like pathology. Aim of the study: It was investigated whether a further reduction of Jangwonhwan (LMK03-Jangwonhwan) retains the potency to suppress the AD-like pathology. Materials and Methods: The transgenic mice of Alzheimer disease, Tg-APPswe/PS1dE9, were fed LMK03-Jangwonhwan consisting of two of the herbs, white Poria cocos (Schw.) Wolf and Angelica gigas Nakai, which could protect the AD-like pathology at 300. mg/kg/day of dose for 3 months. In vitro cell biological study, immunohistological and ELISA (enzyme-linked immunosorbent assay) analyses were used to assess its neuroprotective effects against Aβ-induced cell death, and the Aβ accumulation and plaque deposition in the brain. Results: In vitro study with SH-SY5Y neuroblastoma cells showed that LMK03-Jangwonhwan could protect from cytotoxicity induced by hydrogen peroxide or oligomeric Aβ1-42. Tg-APPswe/PS1dE9 mice were administered LMK03-Jangwonhwan at 300mg/kg/day for 3 months from 4.5 months of age. Immunohistological and ELISA analyses showed that LMK03-Jangwonhwan partially reduced Aβ1-42 and Aβ1-40 levels and β-amyloid plaque deposition in the brain of Tg-APPswe/PS1dE9 mice. However, LMK03-Jangwonhwan poorly suppressed accumulation of reactive oxidative stress in the hippocampus of Tg-APPswe/PS1dE9 mice and inefficiently improved the expression of phospho-CREB and calbindin, the cellular factors that were down-regulated in AD-like brains. Conclusions: These results suggest that LMK03-Jangwonhwan has a potency to inhibit AD-like pathology at a detectable level, but LMK03 is not likely to retain the major ability of LMK02-Jangwonhwan to modify AD pathology in several AD-related molecular parameters. © 2010. | - |
dc.language | English | - |
dc.title | A modified preparation (LMK03) of the oriental medicine Jangwonhwan reduces Aβ1-42 level in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease | - |
dc.type | Article | - |
dc.relation.issue | 3 | - |
dc.relation.volume | 130 | - |
dc.relation.index | SCI | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 578 | - |
dc.relation.lastpage | 585 | - |
dc.relation.journaltitle | Journal of Ethnopharmacology | - |
dc.identifier.doi | 10.1016/j.jep.2010.05.055 | - |
dc.identifier.wosid | WOS:000280869900018 | - |
dc.identifier.scopusid | 2-s2.0-77954954791 | - |
dc.author.google | Seo J.-S. | - |
dc.author.google | Jung E.-Y. | - |
dc.author.google | Kim J.-H. | - |
dc.author.google | Lyu Y.-S. | - |
dc.author.google | Han P.-L. | - |
dc.author.google | Kang H.-W. | - |
dc.contributor.scopusid | 한평림(7201947605) | - |
dc.date.modifydate | 20230901081001 | - |